|
| | | | |
|
 | | THREE RIVERS PHARMACEUTICALS, LLC PROTECTS ITS INTELLECTUAL PROPERTY | | | Three Rivers Pharmaceuticals, LLC | | 06/06/2007 | | | Three Rivers Pharmaceuticals, LLC, a leading specialty drug manufacturer today announced that it has sued Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited for infringement of Three Rivers' United States Patent No. 6,720,000. The '000 patent is directed to a new and important process for producing ribavirin pellets using wet granulation. Ribavirin is a synthetic nucleoside analog with broad spectrum antiviral properties used to treat patients with Hepatitis C and other viral infections.
The lawsuit against Zydus and Cadila, now pending in the United States District Court for the Eastern District of Virginia, seeks to enjoin those defendants from making, selling or importing finished dosage forms of ribavirin believed to be made by Three Rivers' patented process.
"We had hoped to confirm Zydus' and Cadila's respect of our intellectual property without the need for litigation," said Donald Kerrish, Three Rivers' President and CEO, "but they refused to provide us with any meaningful assurance that Zydus and Cadila had not used and would not use our patented process."
Three Rivers Pharmaceuticals is a privately held company headquartered in Cranberry Township, Pennsylvania and focuses in specialized therapies. Ribasphere(R), Three Rivers' ribavirin drug product produced by the '000 patent process, was approved by the U.S. Food & Drug Administration in April 2004.
SOURCE Three Rivers Pharmaceuticals, LLC | |
|
| | | View similar articles: | | |
| | | |
|
 | People who viewed this article were also interested in |  | |  |
|
| Other articles from Three Rivers Pharmaceuticals, LLC | | | |
|
|